Two of my all-time favorite creatures
I am almost
ashamed of this posting. Almost. I found it trolling for stock-market tips,
but subsequently verified it with some legitimate bio-investigation. It appears that an outfit that calls itself
Clovis Oncology has ascertained that its new oral drug Rubraca improves PFS
(Progression Free Survival) to a significant degree. While not the Holy Grail, this certainly is
welcome progress. Clovis stock promptly shot up 17%.
If you have OVCA, heaven forfend, make sure
your oncologist knows about this new stuff.
Note that I
am definitely not recommending that you sink your nest egg into Clovis stock
(CLVS; $6.14/share as of right now). As
far as I can see, Clovis has yet to make a profit. But I hope someday soon they do.
No comments:
Post a Comment